ASTROCYTOMA, IDH-MUTANT, GRADE 3
Clinical trials for ASTROCYTOMA, IDH-MUTANT, GRADE 3 explained in plain language.
Never miss a new study
Get alerted when new ASTROCYTOMA, IDH-MUTANT, GRADE 3 trials appear
Sign up with your email to follow new studies for ASTROCYTOMA, IDH-MUTANT, GRADE 3, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo aims to slow aggressive brain tumors
Disease control Not yet recruitingThis study tests whether adding the targeted drug vorasidenib to standard chemotherapy (temozolomide) after radiation can slow tumor growth better than chemo alone in people with a specific, aggressive brain tumor (grade 3 IDH-mutated astrocytoma). About 408 newly diagnosed patie…
Matched conditions: ASTROCYTOMA, IDH-MUTANT, GRADE 3
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
New hope for brain cancer: immune booster and drug combo tested
Disease control Not yet recruitingThis study tests two drugs—retifanlimab (an immunotherapy that helps the immune system attack cancer) and DFMO (which slows tumor growth)—in people with progressive high-grade gliomas, aggressive brain tumors. The goal is to find the safest and most effective dose and see if the …
Matched conditions: ASTROCYTOMA, IDH-MUTANT, GRADE 3
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 08, 2026 12:01 UTC